| EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 55 (2), 245-264, 2011 | 2460 | 2011 |
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2182 | 2017 |
| Performance of transient elastography for the staging of liver fibrosis: a meta-analysis M Friedrich–Rust, MF Ong, S Martens, C Sarrazin, J Bojunga, S Zeuzem, ... Gastroenterology 134 (4), 960-974. e8, 2008 | 1889 | 2008 |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1662 | 2018 |
| Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography M Friedrich-Rust, K Wunder, S Kriener, F Sotoudeh, S Richter, J Bojunga, ... Radiology 252 (2), 595-604, 2009 | 924 | 2009 |
| Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir C Sarrazin, TL Kieffer, D Bartels, B Hanzelka, U Müh, M Welker, ... Gastroenterology 132 (5), 1767-1777, 2007 | 781 | 2007 |
| Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin T Berg, M von Wagner, S Nasser, C Sarrazin, T Heintges, T Gerlach, ... Gastroenterology 130 (4), 1086-1097, 2006 | 698 | 2006 |
| Resistance to direct antiviral agents in patients with hepatitis C virus infection C Sarrazin, S Zeuzem Gastroenterology 138 (2), 447-462, 2010 | 669 | 2010 |
| Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 S Zeuzem, R Hultcrantz, M Bourliere, T Goeser, P Marcellin, ... Journal of hepatology 40 (6), 993-999, 2004 | 645 | 2004 |
| A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis S Buch, F Stickel, E Trépo, M Way, A Herrmann, HD Nischalke, M Brosch, ... Nature genetics 47 (12), 1443-1448, 2015 | 601 | 2015 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 564 | 2014 |
| Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ... Gastroenterology 152 (8), 1975-1984. e8, 2017 | 532 | 2017 |
| The importance of resistance to direct antiviral drugs in HCV infection in clinical practice C Sarrazin Journal of hepatology 64 (2), 486-504, 2016 | 526 | 2016 |
| Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure A Kribben, G Gerken, S Haag, S Herget–Rosenthal, U Treichel, C Betz, ... Gastroenterology 142 (4), 782-789. e3, 2012 | 505 | 2012 |
| Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis M Friedrich-Rust, MF Ong, E Herrmann, V Dries, P Samaras, S Zeuzem, ... American Journal of Roentgenology 188 (3), 758-764, 2007 | 494 | 2007 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 487 | 2022 |
| Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients TL Kieffer, C Sarrazin, JS Miller, MW Welker, N Forestier, HW Reesink, ... Hepatology 46 (3), 631-639, 2007 | 476 | 2007 |
| Treatment predictors of a sustained virologic response in hepatitis B and C A Kau, J Vermehren, C Sarrazin Journal of hepatology 49 (4), 634-651, 2008 | 460 | 2008 |
| Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues F van Bömmel, RA de Man, H Wedemeyer, K Deterding, J Petersen, ... Hepatology 51 (1), 73-80, 2010 | 443 | 2010 |
| SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders C Sarrazin, R Rouzier, F Wagner, N Forestier, D Larrey, SK Gupta, ... Gastroenterology 132 (4), 1270-1278, 2007 | 419 | 2007 |
